Amryt exploring its 2017 funding options
Published 13/11/2016 | 02:30
Dublin-listed Amryt Pharma is examining its options for a necessary fundraising at the end of next year.
Chief executive Joe Wiley said the company has enough money to develop its products until then and is "looking at all our funding options right now, actively, to fund the further development of our products".
"Given the late stage nature of our business, we have the opportunity to explore both venture debt options as well as equity," he added.
It aims to develop its lead product as a treatment for the rare skin disorder epidermolysis bullosa, made famous by the well-known Channel 4 documentary The Boy Whose Skin Fell Off.
The company aims to begin a phase-3 study on the product in the first quarter of 2017, and hopes to be able to launch it on the market in 2019.
The product is already approved in Europe as a treatment for so-called "partial thickness wounds" - injuries involving the loss of skin down as far as a layer known as the "upper dermis".
Amryt went public via a reverse takeover of Fastnet Equity earlier this year.
Sunday Indo Business